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October 5, 2010:1263–6ver a 4- to 17-year period, 114 athletes who had participated in
t least 2, and up to 5, consecutive Olympic Games. These athletes
epresented an unique and selected population exposed to extraor-
inarily intense and prolonged athletic conditioning and, there-
ore, were a model to study the question of whether nondiseased
earts with physiologic hypertrophy can be affected adversely (or
ven pathologically) by high-level intensive training over particu-
arly long periods of time.
We have been criticized by Dr. La Gerche and colleagues for
ur focus on the left ventricle in these highly trained athletes (i.e.,
ather than the right ventricle). However, this strategy was based
n certain realistic considerations. First, previous investigations
ave raised concern and/or produced evidence for left ventricular
ysfunction in trained athletes (2,3). Second, with echocardiogra-
hy, we were able to reliably assess changes in left ventricular
orphology and function, which is not easily achieved for the right
entricle with this imaging modality. More precise observations
oncerning right ventricular structure and function in trained
thletes will likely come from studies employing cardiovascular
agnetic resonance imaging.
In summary, our results demonstrate that exercise conditioning
s not responsible itself for left ventricular dysfunction or abnormal
ardiac morphologic changes in long-term Olympic athletes and
onfirms the benign nature of physiologic athlete’s heart, even
nder extreme conditions over extended periods of time. There-
ore, left ventricular dysfunction in trained athletes should raise the
linical suspicion of an underlying pathologic condition.
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rug-Eluting Stents
or Critical Limb Ischemia
eiring et al. (1) presented very compelling data regarding the use
f small diameter (coronary) drug-eluting stents (DES) for the
reatment of infrapopliteal lesions in patients with critical limb
schemia. Their long-term outcomes in regard to patency and limb
alvage suggest that this may become the preferred method of
reatment for these often-challenging patients.The investigators are correct in noting that their data raise
everal important questions that should be addressed in an
ndustry-supported randomized prospective trial to better define
he role of DES for peripheral arterial disease with the goal of
btaining additional U.S. Food and Drug Administration indica-
ions for the use of such stents. These issues can be summarized as
ollows.
First, the biological mechanisms by which DES in the tibial
rteries are able to limit restenosis, whereas in the larger-caliber
uperior femoral artery most DES trials have been less promising,
eeds to be better studied. Second, in this patient population,
ltimately clinical outcomes (limb salvage and the relief of rest
ain) and not long-term patency should be the goal. The classic
eaching that “less blood is required to heal tissue than to keep it
ealed” can be applied to the notion that restenosis in this setting
ay occur without clinical consequences. The relationship be-
ween angiographic patency rates and improved clinical outcomes
emains an unanswered question. Finally, the study by Feiring et
l. (1) is similar to nearly every published series of critical limb
schemia patients in regard to the extraordinarily high mortality
ates of this population. This particularly sick population requires
ggressive, multidisciplinary, secondary prevention strategies, and
ore comprehensive approaches to develop data and strategies to
ecrease this high mortality.
We thank Feiring et al. (1) for publishing this data. His efforts
nd treatment strategies have the potential to lead to more
omprehensive, larger-scale efforts to improve the care of this
opulation of ill patients.
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. Although the biologic effect of drug-eluting stents (DES) in
crural arteries needs further investigation, current data suggests
that below-the-knee arterial lesions respond to coronary DES
in a similar fashion. This is not surprising because these 2
arteries are similar in both dimensions and histology. However,
drawing parallels between self-expanding superficial femoral
artery (SFA) DES trials and crural DES implants is unwar-
ranted. The SFA has 4 times the cross-sectional atherosclerotic
burden compared to crural lesions. Additionally, SFA lesions
are far more diffuse and the dynamic stresses are more severe
